Merrion Pharmaceuticals Plc (Merrion) is a product development company. It offers prescription pharmaceutical products to meet unmet needs in healthcare. The company develops various drug forms including tablets, capsules and injections. Merrion portfolio spans indications for the treatment of diseases such as bone metastases, breast cancer, osteoporosis, prostate cancer and deep vein thrombosis. Its patented drug delivery technology, GIPET, enhances absorption levels in the gastrointestinal tract and increases bioavailability. The company has agreements with several pharmaceutical companies; and through its license agreements with Novo Nordisk A/S develops and commercializes oral forms of Novo Nordisk's Insulin and GLP-1, by utilizing the GIPET technology. Merrion is headquartered in Dublin, Ireland.